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Aims Angiotensin(1-7) (Ang1-7) acting at the level of the rostral ventrolateral medulla (RVLM) affects arterial pressure. The
cellular substrate of Ang1-7 remains unknown. We sought to determine which cell types in RVLM could mediate its
actions and whether these are altered in the spontaneously hypertensive rat (SHR).
Methods
and results
Astrocytes, catecholaminergic (CA-ergic) and non-CA-ergic neurones were targeted with adenoviral vectors in orga-
notypic slice cultures from Wistar rats and SHR. Astrocytic Ca2+ signalling was monitored using a genetically engin-
eered Ca2+ sensor Case12. CA-ergic neurones expressed enhanced green fluorescent protein (EGFP) under control
of the PRS × 8 promoter, whereas non-CA-neurones expressed EGFP under control of the synapsin-1 promoter.
Neurones were recorded in whole cell mode while [Ca2+]i was monitored using Rhod-2. RVLM astrocytes
responded to Ang1-7 (200–1000 nM) with concentration-dependent [Ca2+]i elevation. In SHR, the response to
1000 nM was significantly attenuated. The competitive Ang1-7 receptor antagonist A779, but not the AT1 receptor
blocker (losartan), suppressed Ang1-7-induced [Ca2+]i elevations, which were also antagonized by blocking intra-
cellular Ca2+ stores. Ang1-7 evoked no consistent changes in [Ca2+]i or membrane excitability in CA-ergic or
non-CA-ergic neurones in either rat strain.
Conclusion Astroglia are a plausible cellular target of Ang1-7 in RVLM. Our data suggest that astrocytic responsiveness to Ang1-7
is reduced in SHR. We hypothesise that Ang1-7 modulates astrocytic signalling which in vivo may affect local metab-
olism and microcirculation, resulting in changes in activity of RVLM pre-sympathetic neurones and hence blood
pressure.
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1. Introduction
Angiotensin(1-7) (Ang1-7) has emerged as an important component
of the renin–angiotensin system in both peripheral tissues and the
central nervous system.1,2 Ang1-7 is a product of the reaction cata-
lysed by angiotensin-converting enzyme type 2 (ACE-2) and is
thought to act via a G-protein coupled Mas receptor.3 In peripheral
tissues, Ang1-7 counteracts many effects of angiotensin II4 and its
over-expression in the vascular endothelium of the stroke-prone
spontaneously hypertensive rat (SHR) reduces endothelial dysfunc-
tion and blood pressure and also improves haemodynamics.5,6
However, the Mas receptor is also expressed in the brain where
immunofluorescence was particularly evident in many areas associ-
ated with cardiovascular homeostasis, including the nucleus of the
solitary tract, caudal, and rostral ventrolateral medulla (RVLM), para-
ventricular and supraoptic hypothalamic nuclei.7 Acute microinjec-
tions of Ang1-7 into the ventral medulla have been shown to
trigger cardiovascular responses. In anaesthetized rabbits, injections
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into the RVLM were pro-hypertensive, whereas injections into more
caudal parts of the ventrolateral medulla decreased blood pressure
and heart rate.8 In un-anaesthetized normotensive rats microinjec-
tions of Ang1-7 into RVLM also resulted in an increase in blood
pressure but, interestingly this effect was absent in animals subject
to mild physical exercise.9 Yamazato et al.10 chronically over
expressed ACE-2 in the ventrolateral medulla of the rat using viral
vectors with the aim to produce a lasting increase in Ang1-7 synthesis.
In the SHR, this resulted in a gradual reduction in mean arterial
pressure (significant after 4th week), although the same procedure
had no detectable effect in normotensive Wistar-Kyoto rats.10
Taken together these observations indicate that Ang1-7 has impor-
tant modulatory effects on central autonomic control of arterial
pressure and that one site of its action in the brain is the RVLM.
However, the cellular substrate through which Ang1-7 mediates its
effects in the RVLM remains elusive. The objective of this study was
therefore to identify which of the three cell types most abundant in
the RVLM [e.g. catecholaminergic (CA-ergic) neurones, non-CA-ergic
neurones, and astrocytes] are responsive to the acute application of
Ang1-7 and whether any Ang1-7 effects are altered in the SHR. The
reason for looking at the ventral medullary CA-ergic neurones specifi-
cally is that these neurones are widely implicated in control of sym-
pathetic outflow and, therefore of cardiovascular homeostasis
(reviewed by Dampney et al.11 and Guyenet12). Several recent
studies suggest an important contribution of RVLM glutamatergic
neurones to the maintenance of sympathetic outflow.11,13,14 Finally,
astrocytes have recently emerged as an active component of
various complex central mechanisms and it is now clear that their
role in the brain is by no means limited to just providing structural
and metabolic support to neurones. Astrocytes can affect neuronal
activity in a variety of ways. This may include release of glutamate,
ATP, or other signalling molecules. Moreover, one most intriguing
feature of these cells is their ability to regulate microcirculation and
participate in coupling of neuronal activity and local blood flow.15–17
In this study, we have adopted a novel technical approach based on
targeted expression of genes in the above-mentioned three key cellu-
lar populations in question: CA-ergic neurones, non-CA-ergic neur-
ones, and astrocytes. For this purpose, we used adenoviral vectors
(AVV) with cell-specific promoters. In addition, we introduce here a
novel genetic tool for Ca2+ imaging in astroglia AVV-sGFAP-Case12.
2. Methods
Animal procedures were carried out according to the United Kingdom
Home Office Guidelines on Animals (Scientific Procedures) Act of
1986, consistent with the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health (NIH Publi-
cation No. 85-23, revised 1996) and approved by the University of
Bristol Ethical Review Group (UB/05/035). In total, approximately 45
Wistar rats (WR) and 20 SHR pups were used, animals were originally
purchased from Harlan UK.
2.1 Viral-cell type targeting strategy
To target the three chosen different cell types we used AVV with cell-
specific promoters. In order to study effects of Ang1-7 specifically in
astrocytes, we have generated a novel vector AVV-sGFAP-Case12,
where a recently described genetically encoded Ca2+ sensor Case1218
is expressed under control of a transcriptionally enhanced compact pro-
moter of the glial acidic fibrilatory protein, GFAP.19
CA-ergic neurones were made fluorescent by exposing slices to the
AVV-PRS × 8-enhanced green fluorescent protein (EGFP).20 From the
previous studies, we know that PRS × 8 drives expression in many
CA-ergic nuclei such as locus coeruleus,20 A2 and RVLM.21 We have
also demonstrated directly using micro-amperometry that PRS × 8 tar-
geted cells in RVLM slices are releasing catecholamines and therefore
are from C1 and possibly A1 cell groups. Finally, we took advantage of
the previously found feature of the human synapsin-1 promoter, which
drives expression in many neuronal types and is highly selective for neur-
ones over astroglia, but is almost inactive in CA-ergic neurones.21 Thus,
when slices were exposed to AVV-sSYN-EGFP, fluorescent neurones
could be expected to be glutamatergic or possibly of some other
type, excluding CA-ergic. In AVV-sSYN-EGFP, transcriptional amplifi-
cation strategy was applied to synapsin-1 to increase the level of transgene
expression.19 To confirm that AVV with PRS × 8 and sSYN promo-
ters target different neuronal types, we have transduced cultured slices
(n ¼ 6) with a mixture of AVV-PRS × 8-DsRed2 and AVV-sSYN-EGFP.
Slices were then imaged 7–8 days later in the same way as those used
for recordings (Supplementary material online, Figure S1A–C). Out of
the total 153 neurones (seven fields of view from six slices), we only
found three cells (,2%) with a clear co-localization of DsRed2 and
EGFP (Supplementary material online, Figure S1D; those are likely to be
cholinergic neurones from the nucleus ambiguous which occasionally
migrate towards the edge of the slices and are sensitive to both promo-
ters). Hence, our sampling errors in terms of distinguishing between local
CA-ergic neurones (able to activate PRS × 8 promoter) and
non-CA-ergic neurones (where SYN promoter is active) is negligible.
2.2 Generation of AVV-sGFAP-Case12
and AVV-sSYN-EGFP
To construct the AVV-sGFAP-Case12 shuttle vector pXcX-mCMV/
GfaABC1D-Case12, a lentiviral shuttle vector pTYF-mCMV/GfaABC1D-
Case12 was first made by replacing the SpeI/NotI EGFP fragment in
pTYF-mCMV/GfaABC1D-EGFP19 with NheI/NotI Case12 fragment from
pCase12.18 The I-SceI fragment from pTYF-mCMV/GfaABC1D-Case12
containing the expression cassette mCMV/GfaABC1D-Case12 was then
swapped into the same sites of the pXcX-Sw-linker which then was
recombined into an adenoviral vector named AVV-sGFAP-Case12. To
produce the AVV-sSYN-EGFP shuttle vector pXcX-mCMV/SYN-EGFP,
I-SceI fragment from pTYF-mCMV/SYN-EGFP19 harbouring mCMV/
SYN-EGFP expression cassette was swapped into the I-SceI sites of
pXcX-Sw-linker which then was recombined into an adenoviral vector
named AVV-sSYN-EGFP.
2.3 Slice culture and viral transduction
As described previously,22,23 7 to 9-day-old Wistar or SHR pups were
sacrificed by halothane overdose and used to prepare 250 mm brainstem
slices. Slices were cut rostrally to obex (a few more caudal slices were
also used, see below) under sterile dissection solution, plated onto Milli-
pore membranes and kept at the interface between the feeding medium
(pH 7.3) and humidified atmosphere (5% CO2, 378C). For experiments
with astrocytes, OPTI-MEM-based medium was used. For imaging neur-
ones, Neurobasal-based culturing medium was employed. In both cases,
the medium was changed three times a week. Cultures were used for
experiments between 7 and 14 days in vitro. AVV were added to the
media at the time of plating as described before.24
2.4 Ca21 imaging and patch clamp
For recording, slices and underlying membrane were transferred into a
recording chamber where they were continuously superfused by
either bicarbonate-based artificial cerebro-spinal fluid (ACSF), as in22 or
HEPES-buffered ACSF. We have not noticed any obvious difference in
basal properties of the cells or their responses to drugs with these
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different types of ACSF and therefore the data are pooled. Ca2+ imaging
in astrocytes was carried out using time-lapse mode (every 2 s) using a
Leica confocal SP1 scanner with 488 nm excitation. Intensity of the
laser was kept to the minimum to avoid quenching of the Case12 fluor-
escence. Electrophysiological recordings and Ca2+ imaging of selected
neurones were carried out as described before.22,25 Briefly, EGFP-
fluorescent neurones were visualized using 488 nm light, patched with
pipettes filled with Rhod-2 (0.5 mM) and recorded in current-clamp
mode using a SEC-05LX amplifier (NPI, Germany). The data were
acquired and analysed using Spike2 software (Cambridge Electronic
Design, UK). Green laser light (543 nm) was used to excite Rhod-2.
Changes of [Ca2+]i in individual cells were assessed by changes in relative
fluorescence intensity (F/F0, where F indicates peak fluorescence intensity
and F0 denotes resting fluorescence intensity measured before the arrival
of the drug in the recording chamber).
2.5 Drugs and their application
After a stabilization period of at least 10 min, drugs were added into the
perfusion medium and the effects were observed during a 5 min period.
AngII, 2-Aminoethyl diphenyl borate (2-APB), cyclopiazonic acid (CPA),
and ATP-K salt were from Sigma (UK). Ang1-7 was from Bachem (UK)
and Ang1-7 antagonist A779 was from GeneScript Corp (USA). Losartan
was a gift from Merk, Sharp, and Dohme. Rhod-2 (tripotassium salt) was
supplied by Cambridge Bioscience (UK). In some neurones, 600 and
1000 nM concentrations of Ang1-7 were applied sequentially after a
5–10 min wash.
2.6 Calculations and statistics
All values in this text are mean+ SEM, n refers to the total number of
cells in each population unless stated otherwise. Ca2+ responses to
Ang1-7 in astrocytes widely varied in their amplitude, time course, and
overall shape of response, making meaningful evaluation of these par-
ameters difficult. Therefore, for evaluation purposes, we decided to disre-
gard the apparent magnitude of Ca2+ change in individual astrocytes but
base our statistics on a fraction of the responsive cells. The threshold was
set to 10% of the baseline fluorescence intensity and the cells where appli-
cation of a drug resulted in a timely (within first 60 s after the drug arrival
into the chamber) elevation in [Ca2+]i were counted as ‘responders’. We
then applied Fisher’s exact test as implemented in GraphPad Prism soft-
ware. In each case, the values were calculated based on experiments
from three to six individual slices from different batches; with the total
number of cells studied for each condition was .50. We also measured
the amplitude of responses in these cells (data not shown) and this evalu-
ation demonstrated the same trends as results presented in the text.
Neuronal [Ca2+]i and electrophysiological parameters were evaluated
using standard approaches22 and differences were examined using Stu-
dent’s paired t-test. Statistical evaluation was carried out using Microsoft
Excel and GraphPad Prism 4.
3. Results
3.1 AVV-sGFAP-Case12 as a Ca21 sensor
in astroglia
Astrocytic [Ca2+]i are known to be highly variable and it was there-
fore beneficial to use a method which would visualize this process
in large numbers of these cells selectively, excluding neurones. To
that end, we have generated AVV-sGFAP-Case12, its map is shown
in Figure 1A. The initial characterization of Case12 in cell lines was
published earlier.18 Application of AVV-sGFAP-Case12 to organotypic
slice cultures led to the expression of bright fluorescence in numer-
ous astrocytes across various areas of the slice (Figure 1B). In order
to further confirm the specificity of AAV-sGFAP-Case12 to astroglia,
immunofluorescent staining of the ventral medulla from rats injected
with this vector was performed, essentially as previously described.19
Case12 (green) was well co-localized with GFAP staining (red),
consistent with previous reports (Figure 1C). In accordance with pre-
vious observations, Case12 was photostable only at moderate levels
of illumination and therefore for time-lapse imaging laser intensity
was kept at low levels to avoid quenching. As this vector has not
been used for imaging astrocytes before, it was important to obtain
an estimate of the response which could be anticipated when the
cells were maximally activated. We therefore applied 100 mM of
ATP, one of the strongest activators of the astrocytic Ca2+ signalling,
to three slice cultures. As shown in Figure 1D and E, ATP resulted in a
characteristic Ca2+ response in 55% of astrocytes with an average
increase of fluorescence intensity of 65%, although some individual
cells exhibited Ca2+ elevations in excess of 300%. Thus,
AVV-sGFAP-Case12 is a highly sensitive genetic tool for imaging
changes in [Ca2+]i in astroglia. Its sensitivity compares with that of a
conventional chemical indicator Rhod-2 (Supplementary material
online, Figure S2).
3.2 Effects of Ang1-7 on astrocytes
Only in the slices containing the rostral ventral medulla could the
responses to Ang1-7 (200, 600, 1000 nM) be detected. Cells in
slices at the level of the obex and caudal to it were essentially non-
responsive (five slices, n. 50 data not shown).
Ang1-7 (200, 600, 1000 nM) triggered intracellular Ca2+ elevations
or waves in 6–41% of WR astrocytes, the response was maximal at
600 nM. Thus, the difference between the effect of 200 and 600 nM
was highly significant, but between 600 and 1000 nM was not, in
spite of an obvious trend (Figure 2A). Interestingly, there was a
lower incidence of intracellular Ca2+ elevations in astrocytes in
response to Ang1-7 in SHR compared with astrocytes from WR.
This difference was significant at 1000 nM (P, 0.05; Figure 2A).
Ang1-7 induced fairly slow [Ca2+]i elevations which in some cells
was maintained even after the drug was discontinued (Figure 2B).
Ang1-7 antagonist A779 (200 mM) blocked the effect of Ang1-7 in
WR astrocytes (P, 0.01, n ¼ 64, Figure 2C). On the other hand,
the AT1 receptor blocker losartan (1 mM) did not attenuate the
response to 600 nM Ang1-7 (P. 0.1, n ¼ 84, Figure 2C).
Two intracellular Ca2+ store antagonists, 2-APB (100 mM) and
CPA (10 mM) were used to test whether the effect of Ang1-7 is
store dependent. Slices were pre-incubated in these drugs for 5 min
after which Ang1-7 600 nM was co-infused. In both cases, Ang1-7
effects were strongly attenuated (P, 0.05, n ¼ 89 and n ¼ 72 corre-
spondingly, Figure 2C). Therefore, Ca2+ elevations evoked by Ang1-7
are likely to involve Ca2+ release from intracellular stores.
3.3 Neurones
In slices from normotensive WR animals Ang1-7 (200–1000 nM) had
essentially no effect on either CA-ergic (PRS × 8 targeted) or
non-CA-ergic (SYN targeted) neurones in RVLM slices prepared
exactly like those for imaging astrocytes in terms of [Ca2+]i
(Figure 3A) or resting membrane potential (RMP) (Figure 3B). Similarly,
in slices prepared from SHR, Ang1-7 200 nM had no significant effects
on either [Ca2+]i or RMP (Figure 4; P. 0.1 in all cases). In a few
additional experiments, higher concentrations of Ang1-7 (600 and
1000 nM) were tested on neurones in SHR slices but no clear
effects were detected in either case. Passive membrane resistance
also did not change (data not shown). L-glutamate washed at the
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Figure 1 Characterization of the novel [Ca2+]i imaging tool, AVV-sGFAP-Case12. (A) Layout of the AVV-sGFAP-Case12. Note that minimal CMV
core promoter (mCMV) fused in the antisense orientation to the compact astroglial promoter (GfaABC1D) serves to co-express an artificial tran-
scriptional enhancer Gal4p65. For details see Liu et al.19 (B) Case12 expressing astrocytes in an organotypic cultured slice from the rat medulla. (C) In
order to additionally confirm the specificity of AAV-sGFAP-Case12 to astroglia, immunofluorescent staining of the ventral medulla from rats injected
with this vector was performed; essentially as previously described (refer Liu et al.19 for details). Case12 (green) was well co-localized with GFAP
staining (red), consistent with previous reports. Image size: 250 × 250 mm. (D) Case12 responds with a strong increase in fluorescence intensity
to the application of ATP (100 mM). Left image: before infusion of ATP; right image: 3 min after initiation of ATP application. (E) Traces of fluorescent
intensity measurements from several astrocytes after stimulation with ATP. Note that Case12 has an unprecedented dynamic range and in some cells
fluorescence intensity increases by 300% and more.
Figure 2 Ang1-7 effects on astrocytes imaged within the RVLM in organotypic cultured slices of rat medulla. (A) Ang1-7 (200–1000 nM) causes a
dose-dependent activation of astrocytes in RVLM in WR (grey bars) and SHR (black bars). Statistics are based on the fraction of activated astrocytes
from the total number of recorded cells as indicated on the top of the bars. (B) Example of an Ang1-7-induced Ca2+ response in astrocytes. Ang1-7
induced fairly slow [Ca2+]i elevations which in some cells could last for a long time even after the drug was discontinued. (C) Pharmacological analysis
of Ang1-7 effect. The concentration of 600 nM was used in all these experiments. Note that Ang1-7 effect was blocked by a competitive blocker of the
Mas receptor A779 but not losartan, the Ang II antagonist. Two blockers of intracellular stores, CPA, and 2-APB significantly (P, 0.05) attenuated the
effect of Ang1-7. The right bar represents the effect of 600 nM Ang1-7 alone for comparison.
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end of the experiments as a positive control evoked robust [Ca2+]i
increases (Supplementary material online, Figure S3) and depolariz-
ations (Supplementary material online, Figure S4).
4. Discussion
This study used an innovative approach to identify a cellular substrate
of Ang1-7 in the ventral medulla of rats, by selectively targeting the
three most abundant cell types in that part of the brain—astroglia,
CA-ergic neurones and non-CA-ergic neurones with cell-specific
viral vectors. We found that the only cellular compartment that
responded to Ang1-7 was astroglia, while we could not detect any
consistent evidence of neuronal activation or inhibition.
Although many studies suggest that Ang1-7 has central effects,9,26–31
the cellular substrate of its action in the CNS remains elusive. Several
studies have identified the ventrolateral medulla as a site where
Ang1-7 has important effects on the cardiovascular system. For
example, microinjections of Ang1-7 into the RVLM produced signifi-
cant increases in arterial pressure.32 Interestingly, equimolar doses
of Ang1-7 in the caudal ventrolateral medulla produced a depressor
effect similar to that evoked by angiotensin II and this effect was of
comparable magnitude in WR and SHR.33 Overexpression of ACE-
2 on RVLM of SHR caused a long-lasting hypotensive effect.10 The
mechanism behind this effect of ACE-2 was not identified in these
experiments, but the authors proposed that it may be the result of
faster AngII degradation, rather than a direct effect of Ang1-7. Thus,
these results do not directly conflict with the previously mentioned
data obtained using acute Ang1-7 microinjections, but rather
suggest that chronic effects of ACE-2 in vivo may involve more than
one mechanism and possibly other cell types than neurones.
RVLM harbours a variety of cellular types which could all be
responsible for Ang1-7 actions. The most prominent of the neuronal
populations in that area are CA-ergic neurones from the C1 adrener-
gic and A1 noradrenergic clusters surrounded by non-CA-ergic neur-
ones, many of which use glutamate as the main transmitter.11,13,14 In
addition, as in virtually any other part of the brain, astroglia are also
highly abundant. In order to understand how Ang1-7 mediates its
central effects on arterial pressure, it is essential to localize the cellu-
lar substrate of its action as an initial first step. In this study, we have
used the strategy of selectively targeting three plausible cell types with
cell-specific viral vectors. For visualizing astrocytic Ca2+ signalling, we
selectively targeted astrocytes with a recently described genetically
engineered Ca2+ sensor Case1218 using transcriptionally amplified
glial fibrillitary protein promoter.19 This approach allows monitoring
astrocytic [Ca2+]i without the need to either patch the cells or bulk
load them with esters of Ca2+-sensitive dyes that are non-selective
for any specific cell type. In contrast, cell-specific expression of a
Ca2+ sensor ensured that the fluorescent signal came from astroglia.
We first established that the Case12 sensor has a very high dynamic
range, consistent with previous observations18 using ATP as a positive
control. Ang1-7 had a concentration-dependent effect on astrocytic
Ca2+ and at 1000 nM 40% of WR astrocytes were excited by it.
Interestingly, SHR astrocytes responded to 200 and 600 nM Ang1-7
in a similar way, but the highest concentration (1000 nM) was signifi-
cantly less effective (Figure 2A), suggesting that SHR Ang1-7 signalling
might be compromised, although as long as we do not know the
actual physiological range of Ang1-7 in the brain, this remains a
speculation. The effect of Ang1-7 was specific and obviously mediated
Figure 3 Ang1-7 (200–1000 nM) has no significant effects on either CA-ergic or non-CA-ergic neurones in WR. Ang1-7 effects on [Ca2+]i, (A) and
the RMP (B). CA-ergic neurones were targeted with viruses containing PRS × 8 promoter (black bars), non-CA-ergic neurones were targeted with
vectors with sSYN promoter (patterned bars). Concentrations of Ang1-7 are shown next to the bars. Neither parameter was significantly affected at
any concentration (P. 0.1 in all cases). Six to eight neurones were used for each measurement. Note that at the end of the recording we verified that
the cells were viable and the infusion was functional using a standard agonist (L-glutamate).
Figure 4 Ang1-7 (200 nM) has no significant effects on either
CA-ergic or non-CA-ergic neurones in SHR. Slices were treated
the same way as Figure 3. Ang1-7 was without effect on these neur-
ones (P . 0.1 in all cases), numbers of cells indicated on the plot.
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by Mas receptor because A799 almost completely eliminated it, while
AT1 receptor blocker losartan was without effect (Figure 2C). In
addition, Ca2+ was released at least in part from the intracellular
stores because pre-incubation with CPA and 2-APB strongly attenu-
ated the effect of 600 nM Ang1-7.
Astrocytes are rapidly emerging as a very important component of
central homeostatic mechanisms.34 Previously, it was demonstrated
that in human astrocytoma cell lines, Ang1-7 stimulated release of
prostaglandin but caused no consistent effects on intracellular
Ca2+35. The lack of Ca2+ responses in that previous study could be
explained by the differences between the astrocytic cell lines and
astrocytes studied within their usual cellular environment albeit in
organotypic slices. Moreover, it is not impossible that there are
regional differences in astrocytic [Ca2+]i sensitivity to Ang1-7, at
least in our experiments we could only obtain reliable [Ca2+]i
responses in slices cut at the locations corresponding to the rostral,
rather than caudal VLM (data not shown). However, our study is con-
sistent with that of Tallant et al.35 in that astrocytes are sensitive to
Ang1-7 and therefore could potentially mediate its actions in the
brain. How exactly Ang1-7 actions on astrocytes may be converted
into changes in neuronal activity affecting autonomic homeostasis
such as changes in sympathetic outflow is not known at present.
One particularly interesting possibility is that by modulating astro-
cytes, Ang1-7 could affect microcirculation within the brain. Indeed,
several recent studies have established a functional link between
astrocytic activity and brain microvessels (reviewed by Iadecola and
Nedergaard16). It was demonstrated that under the conditions
when oxygen levels are low and astrocytic Ca2+ signalling is elevated,
astrocytes can release lactate. Lactate then attenuates a transporter-
mediated prostaglandin E2 uptake from the extracellular space and
the accumulating prostaglandin causes vasodilatation.15 If Ang1-7 is
able to facilitate astrocytic Ca2+ signalling in RVLM as suggested by
our data and, in addition stimulates prostaglandin release,35 it could
play a role in controlling microcirculation in this critical area of the
brain. In this way, Ang1-7 could play a role in the control of sympath-
etic outflow and blood pressure, which would be consistent with the
reported beneficial effect of ACE-2 overexpression in RVLM of
SHR.10
Finally, we studied the effects of Ang1-7 on CA-ergic and
non-CA-ergic neurones in RVLM slice cultures. For studies of
CA-ergic neurones, we used a previously tested approach22 based
on EGFP expression in these cells with AVV bearing an artificial
PRS × 8 promoter.20,36 To label non-CA-ergic neurones, we took
advantage of a previously identified feature of the SYN-1 promoter
which was inactive in CA-ergic neurones.21 The fact that SYN-1
targets a different population of neurones from PRS × 8 was verified
in this study directly (Supplementary material online, Figure S1). The
EGFP-positive neurones were recorded using patch pipettes and
filled with Rhod-2 for Ca2+ imaging. However, we were unable to
demonstrate direct effects of Ang1-7 on either CA-ergic or
non-CA-ergic neurones in RVLM of either WR (200–1000 nM) or
SHR by looking at the changes in the electrical behaviour of the neur-
ones or their [Ca2+]i. The methods used here were indentical to
those in our previous study where these neurones did respond to
Ang II22 and we confirmed that the cells were viable in the present
experiments using L-glutamate at the end of the recording. It is there-
fore hard to imagine that the lack of Ang1-7 effects in the present
experiments is a technical artefact. Yamazato et al.10 also noted that
in their hands Ang1-7 had no effect on neuronal activity, although
did not show the actual data. Thus, the neuronal substrate for the
acute pressure responses reported after Ang1-7 micronjections in
this area, as reported by Silva et al.32 remains unclear. In summary,
the present results suggest that astroglia could be the key cellular
compartment mediating Ang1-7 actions on cardiovascular homeosta-
sis at the level of RVLM.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
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